Multiple Regressions: Associations Between Baseline TTV and Disability Measures							
Predictor		EDSS	LCVA-25	SDMT	T25FW	9-HPT	MSFC-4
Thalamic volume — mm³	β	0.241	4.767	3.878	1.381	-1.479	0.120
	P-value	0.706	0.510	**<0.001**	0.868	0.762	**0.003**
Treatment group (Placebo)	β	-0.244	-2.388	-1.344	0.596	6.528	-0.152
	P-value	0.104	0.286	0.395	0.760	0.567	0.109
MS Subtype (SPMS)	β	0.322	-2.285	2.012	4.927	1.202	-0.207
	P-value	0.090	0.286	0.314	0.047	0.934	0.084
Disease duration	β	0.005	-0.033	0.027	0.055	0.756	<0.001
	P-value	0.600	0.742	0.770	0.631	0.260	0.993
Age	β	-0.001	-0.129	-0.271	-0.268	-1.997	0.002
	P-value	0.951	0.304	0.021	0.064	0.019	0.729
Sex (Female)	β	-0.027	0.756	7.415	0.811	-10.706	0.397
	P-value	0.874	0.322	**<0.001**	0.714	0.408	**<0.001**
Ethnicity (Not hispanic)	β	0.016	0.756	10.260	-6.885	18.647	0.288
	P-value	0.971	0.875	0.023	0.215	0.566	0.284
Intracranial volume — mm³	β	<0.001	0.001	< -0.001	< -0.001	-0.005	<0.001
	P-value	0.518	0.610	0.973	0.496	0.537	0.588
Overall P-value		**0.007**	**0.002**	**<0.001**	**0.006**	0.925	**<0.001**
F statistic		1.805	1.992	6.262	1.836	0.658	3.172
Adjusted R-squared		0.113	0.135	0.453	0.116	0.057	0.255

Supplemental Table 1: Associations Between Baseline TTV and Disability Measures. Significant p-values shown in bold, determined using Bonferroni correction for 6 outcomes ($p < 0.008$). For interpretability, thalamic volumes are scaled by 10^3 for SDMT, 9-HPT, and MSFC-4; and by 10^4 for EDSS, LCVA-25 and T25FW.